Dr Nelson talks with Dr Patrick Forde about his research showing the benefits of using immunotherapy treatments before surgery in lung cancer patients.
lung cancer
Patient Creates Award to Distinguish the Best Lung Cancer Doctors and Nurses
Posted by | UncategorizedKimmel Cancer Center team is among inaugural recipients (Photo: from left: Christine Hann, Russell Hales, Marilyn Holman, Matt Holman, Hanika Reyes Rodavia) Despite being a scientist, Matt Holman was unsure of the best treatment plan and where to go to find it when his wife Marilyn was diagnosed with small cell lung cancer in 2016. He(...)
Cancer Interception: Kimmel Experts Part of New Stand Up To Cancer Project
Posted by | Research, treatmentStand Up To Cancer launched four new teams aimed at detecting and treating cancer in its earliest stages. Lung cancer expert Julie Brahmer, M.D., is the lead investigator for Johns Hopkins for lung cancer studies based at the Kimmel Cancer Center Thoracic Center of Excellence she directs. Victor Velculescu, M.D., Ph.D., an expert in the(...)
Immunotherapy for Lung Cancer
Posted by | precision medicine, treatmentIt’s lung cancer awareness month. Hear lung cancer expert Julie Brahmer and cancer genetics expert Victor Velculescu explain how immunotherapy is becoming a game changer for certain patients. Learn about the latest advances from our Bloomberg~Kimmel Institute for Cancer Immunotherapy and how we are helping patients with lung cancer live better and longer. Watch the(...)
Lung cancer immunotherapy options expand
Posted by | Issues & PerspectivesPatients and doctors received news this week of the FDA’s approval of the immunotherapy drug pembrolizumab in combination with platinum doublet chemotherapy as first-line therapy for all patients with non-small cell lung cancer, irrespective of patients’ tumor PD-L1 status. The new approval follows the FDA’s decision last November to approve pembrolizumab as a first-line therapy for some(...)
Do you have endocrinologists on the lung cancer team?
Posted by | treatmentEndocrinologists, or hormone doctors, are on your lung cancer treatment team “if it's clinically appropriate for them to be a part of it,” says radiation oncologist Russell K. Hales, M.D. of the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus. Hales notes that “Endocrinologists often look at hormone levels, and we use(...)
What side effects can lung cancer radiation cause?
Posted by | treatmentMany lung cancer patients are concerned about the side effects lung cancer radiation can cause, such as heart or kidney damage, or fertility problems, says radiation oncologist Russell K. Hales, M.D. of the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus. “Any therapy can cause short-term or long-term problems, and side effects,”(...)
How does diet affect lung cancer risk or treatment? Do you have a nutritionist on my care team?
Posted by | Prevention/Screening, treatment“When I meet with patients, I tell them that there are three critical parts to their therapy. The first is local therapy, such as surgery or radiation. The second is chemotherapy, or systemic therapy. And the third is their overall well-being, such as nutrition,” says Russell K. Hales, M.D. Hales, a radiation oncologist at the(...)
How long does it take to test and see test results about lung cancer mutations?
Posted by | Prevention/Screening“Molecular profiling of a tumor has really taken off over the last few years, and a few years ago, it could take several weeks for these results to come back. We can now test for the changes we can target in a lung tumor within four to five days here at Hopkins,” says Russell K.(...)
It seems that more young people in their 30s and 40s are being diagnosed. Are any studies looking at this and can they help younger patients?
Posted by | Research“I'm not aware of data to show that more young people are being diagnosed with lung cancer,” says Russell K. Hales, M.D., a radiation oncologist, at the Johns Hopkins Kimmel Cancer Center on the Johns Hopkins Bayview campus. “But anecdotally, it is what I seem to be seeing as well. What we tend to see(...)